PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract

PharmAla Biotech Holdings Inc. MDXXF, a Toronto-based biotechnology company, has secured a contract to supply MDMA for a clinical trial conducted by Johns Hopkins Medicine. This marks a significant milestone for the company as it expands its role in providing MDMA and its novel derivatives for scientific and medical research. PharmAla specializes in the research, development and manufacturing of LaNeo MDMA and related MDXX class molecules, which have garnered attention for their potential in therapeutic applications.

Supplying Johns Hopkins With GMP Certified MDMA

The CEO of PharmAla Biotech, Nicholas Kadysh, expressed the company's commitment to supporting groundbreaking research globally. “We're looking forward to continuing to provide exceptional service – as well as robust investigational drug product – to researchers in the US and around the world,” Kadysh stated. PharmAla's reputation for producing GMP (Good Manufacturing Practices) MDMA that meets stringent regulatory standards, including those set by the U.S. Food and Drug Administration (FDA), has positioned the company as a key player in the field.

Contract Termination With Red Light Holland

In a recent update, PharmAla Biotech disclosed the termination of its contract with Red Light Holland TRUFF, a partnership that officially ended on September 3, 2024. While the company did not provide details about the reasons behind the termination, the move signals PharmAla’s strategic shift in focus toward other high-profile collaborations and opportunities.

PharmAla To Present Research On APA-01 At European Workshop

In addition to its work with MDMA, PharmAla is excited to share new findings about its proprietary molecule, APA-01, at the upcoming European Behavioural Pharmacology Society (EBPS) Workshop on September 26. Dr. Harpreet Kaur, VP of Research at PharmAla, will present data on APA-01, which is described as an “entactogen with improved safety pharmacology compared to MDMA.” Dr. Kaur emphasized the importance of this work, stating, "We are delighted with our acceptance for Hot Topics, a testament to the work we continue to do in identifying and validating novel MDMA-like molecules with improved safety pharmacology."

Cover image made with AI